China Biotech (01177.HK) announced that the independently developed class 1 innovative drug, Envonalkib (TQ-B3139), also known as "Anluqing", which contains the active ingredient lorlatinib fumarate, has been approved for marketing by the National Medical Products Administration. It can be used to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are ALK-positive and have not been treated with ALK inhibitors.
中生製藥(01177.HK)肺癌創新藥「安洛晴」獲藥監局批准上市
China Biologic Products' (01177.HK) innovative drug for lung cancer, Anlotinib, has been approved for listing by the drug regulatory agency.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.